Diabetes Trial Reveals Important Cardiovascular Safety On AVANDIA
At the 68th Scientific Sessions of the American Diabetes Association in San Francisco, CA, several studies were presented evaluating the impact of blood sugar control to reduce diabetes-related complications in patients.
VADT (Veterans Affairs Diabetes Trial), a large, long-term and independent outcomes study, evaluated whether intensive versus standard blood sugar control can reduce the incidence of major cardiovascular (CV) events associated with diabetes including heart attack, congestive heart failure and CV death.
According to news announced by the ADA, AVANDIA (rosiglitazone maleate) was used in a majority of patients in the study and was not associated with increased deaths. These data are consistent with results from other long-term studies with AVANDIA.
The primary result of VADT did not show that intensive blood sugar control (HbA1c levels below 7%) had a statistically significant effect on reducing major CV events associated with diabetes. However, it was found that there was a favorable trend in reducing all CV events, except CV death, among the patients in the intensive arm. While the VADT did not meet its primary endpoint, it is critical that these results do not detract from what is already known about the benefits of long-term blood sugar control on other serious and potentially life-threatening complications of diabetes, such as kidney failure, blindness and amputation. VADT is an independent study sponsored by the Department of Veterans Affairs.